摘要
目的:观察金龙胶囊先期干预联合肝动脉栓塞介入化疗(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌的临床疗效。方法:将70例原发性肝癌患者随机分为两组,单纯TACE组36例(对照组),TACE+金龙胶囊组34例(治疗组)。对照组进行E-ADM+5-FU+DDP TACE治疗1次;治疗组在对照组的基础上,于治疗前7天始口服金龙胶囊1 g/次,3次/日,连续服用5周。观察两组治疗后肿瘤病灶大小、肝功能指标、中医证候评分、KPS评分及Th1、Th2细胞因子漂移等方面的变化情况。结果:在肿瘤病灶大小变化、肝功能评价指标数值变化、KPS评分值、中医症状评分及Th1、Th2细胞因子浓度变化等多方面,单纯TACE组与金龙胶囊先期干预组比较,有显著性统计学差异(P<0.05)。结论:研究资料显示金龙胶囊先期干预对原发性肝癌具有抑制肿瘤、减毒增效保肝、提高生存质量、增强免疫功能等疗效,且经证实无出血及凝血功能障碍等不良反应。
Objective： The objective of this study was to observe the clinical effects of early treatment with Jin-long capsules combined with transarterial chemoembolization （TACE） in primary liver cancer. Methods： Seventy patients with primary liver cancer were randomly divided into two groups, namely, the contrast group （administered with TACE only） and the treatment group （given TACE and Jin-long capsules）. The contrast group received TACE treatment with E-ADM ＋ 5-Fu ＋ DDP once. By contrast, the treatment group was given 1 g of Jin-long capsules initially and thrice a day before the 7-day TACE regimen began, which lasted for 5 weeks （continuously）. Results： The two groups significantly differed in their tumor lesion size, liver function index, TCM symptomatic score, KPS score, and cytokine switching of Thl and Th2 （P〈0.05）. Conclusions： Clinical research shows that early intervention with Jin-long capsules for primary liver cancer can improve the efficiency of anticancer therapy, minimize adverse reactions, as well as protect the liver, improve the quality of life, and enhance the immune function of patients. Jin-long capsules have no adverse reactions, such as bleeding and coagulation disorders.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第1期45-49,共5页
Chinese Journal of Clinical Oncology
关键词
金龙胶囊
原发性肝癌
TACE
肝功能损害
先期干预
jin-long capsules
primary liver cancer
TACE
liver dysfunction
early intervention
